Curetis to benefit from bioMérieux's BioFire swoop?
This article was originally published in Clinica
Executive Summary
Infectious disease molecular diagnostics specialist Curetis has seen increasing interest in its technology from some of the larger players since the acquisition of rival BioFire Diagnostics by France’s bioMérieux. The Marcy l’Etoile shelled out $450m, plus debt, for BioFire and its FilmArray platform earlier this month, in a deal that was too rich for some analysts (www.clinica.co.uk, 5 September 2013).
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.